Outsourcing in Clinical Trials Southern California24-25 September 2013, La Jolla, CA
The OCT team are proud to announce the arrival of the newest event in the series; Outsourcing in Clinical Trials Southern California. As a result of numerous requests to bring this series to the region, September 2013 will see the launch of a specifically tailored event catering to this life science hub.
With an agenda covering topics relevant to pharma, biotech, virtual and medical device companies, this event offers a unique opportunity to tailor your visit and take away the most valuable and relevant information and network with specific, high profile contacts.
Registration is now open for pharma and biotech executives. To receive more information, please e-mail - firstname.lastname@example.org (limited spaces available)
We are always happy to see photos taken at our events! If you have any you would like to submit, please email email@example.com The Arena Team
The OCT Southern California launch is being developed to allow you to entirely tailor your visit to meet your business needs and objectives. The event agenda is split so that the first day covers content relevant to biotech and pharma companies, and the second day of the event is divided into two, catering separately to virtual pharma and medical device manufacturers.
At Arena International we go to extreme lengths to get to know our audience and cater to their specific needs and wishes. The OCT team lives and breathes conferences in the biotech and pharma space, allowing us to create truly innovative and inspired events. Here are just 7 of the reasons to attend our most popular event series.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news.
We now have a brand new group for the Outsourcing in Clinical Trials series on LinkedIn! Join the group for great ways to network with sponsors, speakers and delegates.
US-based Sunesis Pharmaceuticals has started an investigator-sponsored Phase I/II trial of vosaroxin in combination with azacitidine for the treatment of patients with myelodysplastic syndrome (MDS).
US-based biopharmaceutical firm CytRx has released positive top-line efficacy results from a Phase IIb clinical trial, which evaluated the efficacy and safety of aldoxorubicin compared to doxorubicin in patients with first-line metastatic, locally ad…
Sunovion Pharmaceuticals has released results from a pooled analysis of three Phase III randomised, placebo-controlled trials (Studies 301, 302 and 304) assessing the safety and efficacy of once-daily Aptiom (eslicarbazepine acetate) as adjunctive tr…
US-based Verastem has started an open-label, dose escalation and schedule finding Phase I trial of a dual mTORC1/2 and PI3K inhibitor 'VS-5584' for treatment of patients with advanced solid tumours or lymphoma.
US-based biopharmaceutical firm Portola Pharmaceuticals has released additional results of a Phase II proof-of-concept trial of its investigational Factor Xa inhibitor antidote 'andexanet alfa (PRT4445)', in healthy volunteers who were administered t…